Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma

Autor: Jong, E.J.M. de, Janssen, Q.P., Simons, T.F.A., Besselink, M.G., Bonsing, B.A., Bouwense, S.A.W., Geurts, S.M.E., Homs, M.Y.V., Meijer, V.E. de, Tjan-Heijnen, V.C.G., Laarhoven, H.W.M. van, Valkenburg-van Iersel, L.B.J., Wilmink, J.W., Geest, L.G. van der, Koerkamp, B.G., Vos-Geelen, J. de, Dutch Pancreatic Canc Grp

Publikováno v: the Dutch Pancreatic Cancer Group 2021, ' Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma ', International Journal of Cancer . https://doi.org/10.1002/ijc.33916
International Journal of Cancer, 150(10), 1654-1663. Wiley
International Journal of Cancer, 150(10), 1654-1663. WILEY
International Journal of Cancer, 150(10), 1654-1663. Wiley-Liss Inc.
International Journal of Cancer. Wiley-Liss Inc.

The added value of capecitabine to adjuvant gemcitabine monotherapy (GEM) in pancreatic ductal adenocarcinoma (PDAC) was shown by the ESPAC-4 trial. Real-world data on the effectiveness of gemcitabine plus capecitabine (GEMCAP), in patients ineligibl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98591d77ef223c7b454093ddbecad764
https://research.rug.nl/en/publications/93177b76-85f3-4f86-a692-5baa3607655e